A look At The Results Of Five FTSE Stocks – CSH, HMI, SIXH, FAB And ODX

A look At The Results Of Five FTSE Stocks – CSH, HMI, SIXH, FAB And ODX
Civitas Social Housing plc

Civitas Social Housing Plc (LON: CSH) is a United Kingdom based Real Estate Investment Trust Company. The company creates value for its shareholders by making investments in England and Wales within the housing sector. The company also invests in creating homes for people who need supported living with other support requirements as well. The company has a diversified portfolio of social homes across England and Wales providing accommodation for tenants which are registered with local authorities.

CSH Financial Performance

On 2nd December 2019, the company reported its half year results for the six months ended 30th September 2019. During the period, the main highlighting point for the company was the increase in the valuation of investment property by approximately 24 per cent year on year from £678.7 million as on 30th September 2018 to £841.5 million as on 30th September 2019. In terms of the financial performance, the company reported a rental income increase of 45 per cent to £22.7 million in the first half of the current year. The EPRA Earnings per share for the year was also reported at a massive increase of 118 per cent to 2.29 pence per share.

CSH Share Price Performance

(Source: Thomson Reuters) Daily Chart as on 02-December-19, prior to the close of the market

On 2nd December 2019, at 01:15 P.M GMT, while writing, Civitas Social Housing Plc’s share price was reported to be trading at GBX 88.80 per share, an increase of 0.45 per cent or GBX 0.40 per share, as compared to the previous day’s closing price, which was reported to be at GBX 88.40 per share. The company’s market capitalisation (M-Cap) was reportedly valued to be at GBP 549.62 million with respect to the stock’s current market price.

Harvest Minerals Limited

Harvest Minerals Limited (LON: HMI) is a Subiaco, Australia based mining company that majorly conducts its operations of Mineral exploration and development in the country of Brazil. The company’s flagship, Arapua Fertilizers project is located near Minas Gerais, and has obtained a rolling 4-year trial mining license. The other projects by the company include the likes of Potash Projects in Sergipe as well as Mandacaru Phosphate Project.

HMI Financial Performance

On 2nd December 2019, the company made a press release to announce its final results for the year ended 30th June 2019. The company highlighted that during the period, its flagship product, KPFértil, which is a core fertilizer, was continuously gaining traction from the consumers in the market. In terms of its financial performance, the company’s revenue from fertilizer sales was reported to be at US $1.62 million, as opposed to just US $41,827 in the previous year. The company also reported a gross profit of US $952,901 during the reporting period. The loss from continuing operations before income tax as well as the Net loss for the year were reported at US $3,456,031.

HMI Share Price Performance

(Source: Thomson Reuters) Daily Chart as on 02-December-19, prior to the close of the market

On 2nd December 2019, at 01:20 P.M GMT, while writing, Harvest Minerals Limited’s share price was reported to be trading at GBX 4.202 per share, a decline of 4.50 per cent or GBX 0.198 per share, as compared to the previous day’s closing price, which was reported to be at GBX 4.40 per share. The company’s market capitalisation (M-Cap) was reportedly valued to be at GBP 8.18 million with respect to the share’s current market price.

The beta of the Harvest Minerals Limited’s share has been reported to be at 2.3208. This basically implies that the volatility in the price of the company’s stock, is more than the volatility in the movement of the comparative benchmark index.

600 Group Plc

600 Group Plc (LON: SIXH) is an Elland, United Kingdom based Industrial Engineering company, who’s main business is the production and supply of various precision engineered components as well as Industrial Laser systems in around 100 countries across the world, mainly operating in Europe, North America as well as Australia.

SIXH Financial Performance

On 2nd December 2019, the company posted its half yearly results for the six months ended 28th September 2019. The company reported a 13 per cent year on year increase in the revenue to US $35.7 million as well as a significant 39 per cent year on year growth of the underlying operating profit to US $2.5 million. The underlying Profit before tax was reported at a growth of 28 per cent to US $1.7 million. As per the dividend policy of the company, the management proposed an interim dividend of 0.25 pence per share, which is flatlined, as compared to the Interim dividend declared in the same period during the previous year.

SIXH Share Price Performance

(Source: Thomson Reuters) Daily Chart as on 02-December-19, prior to the close of the market

On 2nd December 2019, at 01:25 P.M GMT, while writing, 600 Group Plc’s share price was reported to be trading at GBX 19.00 per share, an increase of 6.15 per cent or GBX 1.10 per share, as compared to the previous day’s closing price, which was reported to be at GBX 17.90 per share. The company’s market capitalisation (M-Cap) was reportedly valued to be at GBP 21.03 million with respect to the share’s current market price.

The beta of the 600 Group Plc’s share has been reported to be at 0.8555. This basically implies that the volatility in the price of the company’s stock, is less than the volatility in the movement of the comparative benchmark index.

Fusion Antibodies Plc

Fusion Antibodies Plc (LON: FAB) is a Belfast, United Kingdom based Healthcare equipment as well as Healthcare service provider. The company’s primary activities include the research and development around the scientific area of Antibodies, and the moving toward production and commercialisation of products coming into the picture from the research. The company performs various engineering activities such as Antibody Sequencing and Antibody Humanization.

FAB Financial Performance

On 2nd December 2019, the company made a press release to announce its half year results for the six months ended 30th September 2019. The company reported an increase in the number of orders in the first half of FY 2020 as compared to the first half of FY 2019. The revenues for the reporting period were recorded at £1.75 million, as opposed to £0.66 million in the same period during the previous year. The loss for the period in H1 FY 2020 was reported £0.47 million, a reduction as compared to the loss of £0.74 million in H1 FY 2019.

FAB Share Price Performance

(Source: Thomson Reuters) Daily Chart as on 02-December-19, prior to the close of the market

On 2nd December 2019, at 01:30 P.M GMT, while writing, Fusion Antibodies Plc’s share price was reported to be trading at GBX 73.00 per share, a decline of 2.67 per cent or GBX 2.00 per share, as compared to the previous day’s closing price, which was reported to be at GBX 75.00 per share. The company’s market capitalisation (M-Cap) was reportedly valued to be at GBP 16.57 million with respect to the share’s current market price.

Omega Diagnostics Group Plc

Omega Diagnostics Group Plc (LON: ODX) United Kingdom based therapeutic diagnostics organization; its items are focused towards hypersensitivities and immune system type illnesses. Its items incorporate PATHOZYME® Ferritin, PATHOZYME® Luteinizing hormone, PATHOZYME® Prolactin and PATHOZYME® Oestradiol. The organization is headquartered in Alva, Scotland and its shares are listed on the London Stock Exchange where they exchange under the ticker name ODX.

ODX Financial Performance

On 2nd December 2019, the company announced its interim results for the six months ended 30th September 2019. The company reported that the revenue during the period, increased by 6 per cent to £4.46 million, and the gross margin was up by 5.8 per centage points to 67.5 per cent during the period. The Adjusted loss before tax was reported at £0.35 million during the period and the Adjusted loss per share was reported at 0.2 pence per share.

ODX Share Price Performance

(Source: Thomson Reuters) Daily Chart as on 02-December-19, prior to the close of the market

On 2nd December 2019, at 01:35 P.M GMT, while writing, Omega Diagnostics Group Plc’s share price was reported to be trading at GBX 10.4298 per share, an increase of 4.30 per cent or GBX 0.4298 per share, as compared to the previous day’s closing price, which was reported to be at GBX 10.00 per share. The company’s market capitalisation (M-Cap) was reportedly valued to be at GBP 15.03 million with respect to the share’s current market price.

The beta of the Omega Diagnostics Group Plc’s share has been reported to be at 0.7451. This basically implies that the volatility in the price of the company’s stock, is less than the volatility in the movement of the comparative benchmark index.